ArticleTransplantation and cellular therapy2021
Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes.
Open access · hybridAbstract read
In one paragraph
Article in Transplantation and cellular therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 29 citations in OpenAlex.
- Pre-Hematopoietic Cell Transplantation Ruxolitinib in Transplantation-Eligible Patients with Myelofibrosis: Long-Term Outcomes of a Phase II Prospective Study.Transplantation and cellular therapy · 2026Trial
- Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Trial
- Proteomics in myelodysplastic syndromes: towards novel prognostic and diagnostic biomarkers.Biochemia medica · 2026Review
- Long-term survival outcomes of allo-HCT in AML with fludarabine/melphalan conditioning and tacrolimus/sirolimus GVHD prophylaxis.Bone marrow transplantation · 2026Article
- Allogeneic Haematopoietic Stem Cell Transplantation Using Reduced-Intensity Fludarabine, Busulfan and Anti-T-Lymphocyte Globulin With Strategic Donor Lymphocyte Infusion in Older Patients With Myeloid Malignancy.European journal of haematology · 2025Article
- Allogeneic Stem Cell Transplantation: The Relevance of Conditioning Regime Intensity for Myelodysplastic Syndromes (MDS).Current oncology (Toronto, Ont.) · 2025Review
- Treatment of high-risk myelodysplastic syndromes.Haematologica · 2025Review
- Allogeneic hematopoietic cell transplantation in elderly patients with myelodysplastic syndromes: Considerations and challenges.Seminars in hematology · 2024Review
- Evaluating clinically translatable conditioning for platelet gene therapy in murine hemophilia A with inhibitors.Journal of thrombosis and haemostasis : JTH · 2024Article
- Review
- Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working Party.Bone marrow transplantation · 2024Article
- Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes.Transplantation and cellular therapy · 2022Article
- BMT for Myelodysplastic Syndrome: When and Where and How.Frontiers in oncology · 2021Review
- Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes: The Current Landscape and Future Directions.Cancer journal (Sudbury, Mass.)Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
50 authors at 20 institutions in 11 countries.
Betül OranDepartment of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: boran@mdanderson.org.
Kwang Woo AhnCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin; Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, Wisconsin.
Caitrin FrethamCenter for International Blood and Marrow Transplant Research, National Marrow Donor Program/Be The Match, Minneapolis, Minnesota.
Amer BeitinjanehDivision of Transplantation and Cellular Therapy, University of Miami, Miami, Florida.
Asad BasheyDivision of Transplantation and Cellular Therapy, University of Miami, Miami, Florida.
Attaphol PawarodeBlood and Marrow Transplantation Program, Division of Hematology/Oncology, Department of Internal Medicine, The University of Michigan Medical School, Ann Arbor, Mchigan.
Baldeep WirkBone Marrow Transplant Program, Penn State Cancer Institute, Hershey, Pennsylvania.
Bart L ScottFred Hutchinson Cancer Research Center, Seattle, Washington.
Bipin N SavaniDivision of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Christopher BredesonThe Ottawa Hospital Blood and Marrow Transplant Program and the Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Daniel WeisdorfDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota.
David I MarksAdult Bone Marrow Transplant, University Hospitals Bristol NHS Trust, Bristol, United Kingdom.
David RizzieriDivision of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, North Carolina.
Edward CopelanDepartment of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina.
Gerhard C HildebrandtMarkey Cancer Center, University of Kentucky, Lexington, Kentucky.
Gregory A HaleDepartment of Hematology/Oncology, Johns Hopkins All Children's Hospital, St. Petersburg, Florida.
Hemant S MurthyBlood and Marrow Transplantation Program, Division of Hematology-Oncology, Mayo Clinic, Jacksonville, Florida.
Hillard M LazarusUniversity Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio.
Jan CernyDivision of Hematology/Oncology, Department of Medicine, University of Massachusetts Medical Center, Worcester, Massachusetts.
Jane L LiesveldDepartment of Medicine, University of Rochester Medical Center, Rochester, New York.
Jean A YaredBlood & Marrow Transplantation Program, Division of Hematology/Oncology, Department of Medicine, Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, Maryland.
Jean Yves-CahnDepartment of Hematology, CHU Grenoble Alpes, Grenoble, France.
Jeffrey SzerClinical Haematology at Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Victoria, Australia.
Leo F VerdonckDepartment of Hematology/Oncology, Isala Clinic, Zwolle, The Netherlands.
Mahmoud AljurfDepartment of Oncology, King Faisal Specialist Hospital Center & Research, Riyadh, Saudi Arabia.
Marjolein van der PoelMaastricht University Medical Centre, Maastricht, The Netherlands.
Mark LitzowDivision of Hematology and Transplant Center, Mayo Clinic, Rochester, Minnesota.
Matt KalaycioHematology and Medical Oncology, Transplantation Center, Cleveland Clinic, Cleveland, Ohio.
Michael R GrunwaldDepartment of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina.
Miguel Angel DiazDepartment of Hematology/Oncology, Hospital Infantil Universitario Nino Jesus, Madrid, Spain.
Mitchell SabloffDivision of Hematology, Department of Medicine, University of Ottawa and Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Mohamed A Kharfan-DabajaBlood and Marrow Transplantation Program, Division of Hematology-Oncology, Mayo Clinic, Jacksonville, Florida.
Navneet S MajhailBlood & Marrow Transplant Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio.
Nosha FarhadfarDivision of Hematology/Oncology, University of Florida College of Medicine, Gainesville, Florida.
Ran ReshefBlood and Marrow Transplantation Program and Columbia Center for Translational Immunology, Columbia University Medical Center, New York, New York.
Richard F OlssonDepartment of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; Centre for Clinical Research Sormland, Uppsala University, Uppsala, Sweden.
Robert Peter GaleHaematology Research Centre, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom.
Ryotaro NakamuraDepartment of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California.
Sachiko SeoDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan.
Saurabh ChhabraCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin; Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Shahrukh HashmiDepartment of Internal Medicine, Mayo Clinic, Rochester, Minnesota; Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Shatha FarhanHenry Ford Hospital Bone Marrow Transplant Program, Henry Ford Health System, Detroit, Michigan.
Siddhartha GangulyDivision of Hematological Malignancy and Cellular Therapeutics, University of Kansas Health System, Kansas City, Kansas.
Sunita NathanRush University Medical Center, Chicago, Illinois.
Taiga NishihoriDepartment of Blood & Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida.
Tania JainThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Vaibhav AgrawalDivision of Hematology-Oncology, Indiana University School of Medicine, Indianapolis, Indiana.
Ulrike BacherDepartment of Hematology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Uday PopatDepartment of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas.
Wael SaberCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Medical College of Wisconsin · USCleveland Clinic · USJohns Hopkins University · USKing Faisal Specialist Hospital & Research Centre · SALevine Cancer Institute · USMayo Clinic in Florida · USThe University of Texas MD Anderson Cancer Center · USUniversity of Kentucky · USUniversity of Miami · USCentre Hospitalier Universitaire de Grenoble · FRCity of Hope · USDokkyo Medical University · JPDuke University · USFred Hutch Cancer Center · USHenry Ford Health System · USHospital Infantil Universitario Niño Jesús · ESImperial College London · GBIndiana University School of MedicineIsala · NLMaastricht University Medical Centre · NL
Funding
Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2MNCI NIH HHS U24 CA076518
Abstract
Reduced-intensity conditioning (RIC) regimens developed to extend the use of allogeneic hematopoietic stem cell transplantation (HSCT) to older patients have resulted in encouraging outcomes. We aimed to compare the 2 most commonly used RIC regimens, i.v. fludarabine with busulfan (FluBu) and fludarabine with melphalan (FluMel), in patients with myelodysplastic syndrome (MDS). Through the Center for International Blood and Marrow Transplant Research (CIBMTR), we identified 1045 MDS patients age ≥60 years who underwent first HSCT with a matched related or matched (8/8) unrelated donor using an RIC regimen. The CIBMTR's definition of RIC was used: a regimen that incorporated an i.v. busulfan total dose ≤7.2 mg/kg or a low-dose melphalan total dose ≤150 mg/m
Indexed as
Graft vs Host DiseaseMyelodysplastic SyndromesAgedBusulfanHumansMelphalanMiddle AgedSurvival AnalysisTransplantation ConditioningVidarabineBusulfanfludarabineMelphalanVidarabineMDSMelphalanRelapseSurvivalTransplantation
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.